Lung Cancer and Idiopathic Pulmonary Fibrosis : Pathological and Molecular Characterization

Lung Cancer and Idiopathic Pulmonary Fibrosis Clinical Trial

— K-FPI  

Official title:

Lung Cancer and Idiopathic Pulmonary Fibrosis : Pathological and Molecular Characterization

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT03486262
• Other study ID #: NI16034
• Status: Enrolling by invitation
• Start date: February 1, 2018
• Est. completion date: February 2020

Study information

• Verified date: February 2018
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Retrospective inclusion of lung cancers developed in a context of idiopathic pulmonary fibrosis, diagnosed and / or treated in participating centers. The cases are recovered retrospectively from the records of the pulmonology and pathology departments of our various partners.

Description:

Primary objective:

Characterize altered molecular pathways in lung cancer in patients with IPF versus lung cancer in non-IPF patients.

Secondary objectives:

Identify specific therapeutic targets Describe a cohort of lung cancers on IPF (clinical / radiological and pathological data) To study the relationship between neoplastic / preneoplastic lesions and pulmonary parenchyma reshaped by fibrosis.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 100
• Est. completion date: February 2020
• Est. primary completion date: February 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Lung carcinoma

• Idiopathic pulmonary fibrosis

Exclusion Criteria:

• No tumor sample available

Related Conditions & MeSH terms

• Fibrosis
• Idiopathic Interstitial Pneumonias
• Idiopathic Pulmonary Fibrosis
• Lung Cancer and Idiopathic Pulmonary Fibrosis
• Lung Neoplasms
• Pulmonary Fibrosis

Locations

Country	Name	City	State
France	Hopital BICHAT-CLAUDE BERNARD	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Molecular profile of IPF-associated lung carcinomas	Next generation sequencing of carcinomas with Ion S5 XL sequencer and Oncomine™ Comprehensive Panel	1 month / 8 samples
Secondary	Pathological characterization of lung carcinomas	Histological classification of carcinomas and immunohistochemistry with lineage markers	1 month / 8 samples